1. |
Nelson GR. Management of infantile spasms. Transl Pediatr, 2015, 4(4): 260-270.
|
2. |
Go CY, Mackay MT, Weiss SK, et al. Evidence-based guideline update: medical treatment of infantile spasms. Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology, 2012, 78(24): 1974-1980.
|
3. |
Golec W, Sołowiej E, Strzelecka J, et al. new data on indications and safety in paediatric epilepsy. Neurol Neurochir Pol, 2021, 55(5): 429-439.
|
4. |
Pearl PL, Vezina LG, Saneta RP, et al. (2009) Cerebral MRI abnormalities associated with vigabatrin therapy. Epilepsia, 2009, 50(2): 184-194.
|
5. |
Hussain SA, Tsao J, Li M, et al. Risk of vigabatrin-associated brain abnormalities on MRI in the treatment of infantile spasms is dose-dependent. Epilepsia, 2017, 58(4): 674-682.
|
6. |
Bhalla S, Skjei K. Fulminant vigabatrin toxicity during combination therapy with adrenocorticotropic hormone for infantile spasms: three cases and review of the literature. Epilepsia, 2020, 61(10): e159-e164.
|
7. |
Xu Y, Wan L, He W, et al. Risk of vigabatrin-associated brain abnormalities on MRI: a retrospective and controlled study. Epilepsia, 2022, 63(1): 120-129.
|
8. |
Desguerre I, Marti I, Valayannopoulos V, et al. Transient magnetic resonance diffusion abnormalities in West syndrome: the radiological expression of non-convulsive status epilepticus? Dev Med Child Neurol, 2008, 50: 112-116.
|
9. |
Liu SJ, Liu M, Zhang ZB, et al. Reversible abnormalities in brain magnetic resonance imaging of children with infantile spasms during treatments with Vigabatrin. Chin J Appl Clin Pediatr, 2020, 35: 894-898.
|
10. |
Biswas A, Yossofzai O, Vincent A, Go C, et al. Vigabatrin-related adverse events for the treatment of epileptic spasms: systematic review and meta-analysis. Expert Rev Neurother, 2020, 20: 1315-1324.
|
11. |
Walters DC, Arning E, Bottiglieri T, et al. Metabolomic analyses of vigabatrin (VGB)-treated mice: GABA-transaminase inhibition significantly alters amino acid profiles in murine neural and non-neural tissues. Neurochem Int, 2019, 125: 151-162.
|